0001104659-23-122092.txt : 20231129 0001104659-23-122092.hdr.sgml : 20231129 20231129171449 ACCESSION NUMBER: 0001104659-23-122092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231127 FILED AS OF DATE: 20231129 DATE AS OF CHANGE: 20231129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WG Biotech ApS CENTRAL INDEX KEY: 0001753193 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 231453263 BUSINESS ADDRESS: STREET 1: RUNGSTED STRANDVEJ 113 CITY: RUNGSTED KYST STATE: G7 ZIP: 2960 BUSINESS PHONE: 45-45-17-77-77 MAIL ADDRESS: STREET 1: RUNGSTED STRANDVEJ 113 CITY: RUNGSTED KYST STATE: G7 ZIP: 2960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 4 1 tm2330155-5_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-11-27 0 0001722964 Y-mAbs Therapeutics, Inc. YMAB 0001753193 WG Biotech ApS RUNGSTED STRANDVEJ 113 RUNGSTED KYST G7 2960 DENMARK 1 0 0 0 0 Common Stock 2023-11-27 4 P 0 62516 5.4869 A 4342721 D Common Stock 2023-11-28 4 P 0 30671 5.8125 A 4373392 D This transaction was executed in multiple trades at prices ranging from $5.38 to $5.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $5.51 to $6.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Johan Wedell-Wedellsborg is the majority owner of WG Biotech ApS and has sole voting and dispositive power over the shares of the Issuer held by WG Biotech ApS. Mr. Wedell-Wedellsborg serves as a director of the Issuer. In connection therewith, WG Biotech ApS may be deemed to be a director by deputization of the Issuer solely for purposes of Section 16(a) of the Exchange Act. As a result, WG Biotech ApS is listed as a "Reporting Person" in Item 1 and the "Director" box is marked in Item 5 of this Form 4. This filing shall not be deemed an admission by Reporting Person on this Form 4 that such person is a director of the Issuer by deputization. WG Biotech ApS by /s/ Johan Wedell-Wedellsborg 2023-11-29